Evidence map›Paper›PMID 29962076›Full record

ArticleCNS neuroscience & therapeutics2019

Pifithrin-μ modulates microglial activation and promotes histological recovery following spinal cord injury.

Michael D Caponegro, Luisa F Torres, Cyrus Rastegar, Nisha Rath, Maria E Anderson, John K Robinson, Stella E Tsirka

Open access · bronzeAbstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Michael D CaponegroProgram in Molecular and Cellular Pharmacology, Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA.
Luisa F TorresProgram in Molecular and Cellular Pharmacology, Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA.
Cyrus RastegarProgram in Molecular and Cellular Pharmacology, Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA.
Nisha RathProgram in Molecular and Cellular Pharmacology, Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA.
Maria E AndersonBiological Psychology, Department of Psychology, Stony Brook University, Stony Brook, NY, USA.
John K RobinsonBiological Psychology, Department of Psychology, Stony Brook University, Stony Brook, NY, USA.
Stella E TsirkaProgram in Molecular and Cellular Pharmacology, Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA.ORCID 0000-0003-0022-1770
Stony Brook University · US

Funding

Training Program in Pharmacological SciencesT32GM007518 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI GARCIA-DIAZ, MIGUEL · 1985 to 2021
$5.4M
Scholars in BioMedical Sciences (SBMS) Training ProgramT32GM127253 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI TSIRKA, STYLIANI-ANNA (STELLA) E · 2018 to 2022
$689k
NIGMS NIH HHS T32 GM007518NIGMS NIH HHS T32 GM127253
6 · The paper itself

Abstract

backgroundTreatments immediately after spinal cord injury (SCI) are anticipated to decrease neuronal death, disruption of neuronal connections, demyelination, and inflammation, and to improve repair and functional recovery. Currently, little can be done to modify the acute phase, which extends to the first 48 hours post-injury. Efforts to intervene have focused on the subsequent phases - secondary (days to weeks) and chronic (months to years) - to both promote healing, prevent further damage, and support patients suffering from SCI.

methodsWe used a contusion model of SCI in female mice, and delivered a small molecule reagent during the early phase of injury. Histological and behavioral outcomes were assessed and compared.

resultsWe find that the reagent Pifithrin-μ (PFT-μ) acts early and directly on microglia in vitro, attenuating their activation. When administered during the acute phase of SCI, PFT-μ resulted in reduced lesion size during the initial inflammatory phase, and reduced the numbers of pro-inflammatory microglia and macrophages. Treatment with PFT-μ during the early stage of injury maintained a stable anti-inflammatory environment.

conclusionsOur results indicate that a small molecule reagent PFT-μ has sustained immunomodulatory effects following a single dose after injury.

Indexed as

AnimalsAnimals, NewbornBehavior, AnimalContusionsFemaleInflammationMacrophage ActivationMiceMice, Inbred C57BLMicrogliaNeuroprotective AgentsPhagocytosisPrimary Cell CultureRecovery of FunctionSpinal Cord InjuriesSubcellular Fractions2-phenylacetylenesulfonamideNeuroprotective AgentsSulfonamides2-phenylethynesulfonamidecell deathinflammationmicePESPFT-μphagocytosisspinal cord

Identifiers

PMID29962076
PMCPMC6488873
OpenAlexW2810572450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.